top of page

News and announcements

PeptiSystems AB appoints Karin Granath as new CEO;
Co-founder and former CEO Lars Holmberg transitions to become Chief Scientific Officer

17 August 2023 - Uppsala, Sweden

PeptiSystems announces that Karin Granath has joined on June 3rd, 2023, to take over the role of PeptiSystems CEO. PeptiSystems is currently in an expansion phase after having a very successful first year of sales of both peptide and oligonucleotide synthesis instruments since the launch of the products in Q1 2022.


Karin has over 20 years of experience in different leadership positions within the MedTech industry, and she is most recently joining from GE Healthcare, where she had a position as General Manager for a subdivision in the Molecular Imaging space.


Karin Granath comments, “I am very excited to have joined PeptiSystems and look forward to leading the company on our continued expansion journey. I am impressed how PeptiSystems has transferred their deep knowledge in oligonucleotide synthesis to also successfully apply the solid-phase flow through column technology to peptide manufacturing processing.


With 40 years in the field, Lars Holmberg will transition to the Chief Scientific Officer role and focus mainly on product development activities. “I am happy to have Karin onboard to drive the business expansion. This enables me to focus on the important technical aspects of our product portfolio.

Mats Johnson, Chairman of the Board: “Together with his colleagues, Lars has done an excellent job building a profitable company in the first year of sales. Karin will now use her experience to build the company further. We expect continued fast growth in the next three years.

 

About PeptiSystems AB
PeptiSystems, based in Uppsala, Sweden, develop instruments for process development and manufacturing of peptide and oligonucleotide therapeutics based on flow-through column technology. Utilizing the solid-phase synthesis approach, the instruments are designed to reduce solvent consumption, improve synthesis control, and reduce synthesis time while maintaining equal or higher purity and yield compared to what is obtained with current technologies. This new generation of synthesis instruments provides a higher degree of automation and a greener manufacturing process.
For more information, don't hesitate to get in touch with Karin Granath (karin.granath@peptisystems.com) or Lars Holmberg (lars.holmberg@peptisystems.com) at PeptiSystems or visit our website at www.peptisystems.com.

bottom of page